ACOR Financial Facts
Provision for income taxes: 1.78MOperating income (loss): -2.5M
See Full Income Statement
Deferred product revenue-Zanaflex tablets: 29.62M
Total stockholders' equity: 391.64M
See Full Balance Sheet
Earnings History for Acorda Therapeutics, Inc. (ACOR)
|
Expand Research on ACOR
| Next EPS Date | 7/30/13 *Est. | EPS Growth Rate | -75.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +108.6% | Revenue Growth Rate | -12.6% *Last Qtr. |
| Average % Move 1-Wk after EPS | -2.1% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/1/10  |
 |
Q310 | $0.31 | -$0.13 | +$0.44 | N/A | N/A | N/A / N/A | N/A | +18.9% | Details |
| 2/17/11 |
|
Q410 | $0.09 | $0.17 | -$0.08 | $66.8M | $64.26M | N/A / N/A | N/A | +38.6% | Details |
| 5/5/11 |
|
Q111 | $0.08 | $0.18 | -$0.10 | $61.29M | $64.25M | N/A / N/A | N/A | +18.4% | Details |
| 8/1/11 |
|
Q211 | $0.19 | $0.12 | +$0.07 | $65.28M | $66.29M | N/A / N/A | N/A | +13.2% | Details |
| 11/4/11 |
|
Q311 | $0.40 | $0.73 | -$0.33 | $93.03M | $90.78M | N/A / N/A | N/A | +57.3% | Details |
| 2/16/12 |
|
Q411 | $0.45 | $0.18 | +$0.27 | $72.64M | $69.16M | N/A / N/A | N/A | +21.5% | Details |
| 5/3/12 |
|
Q112 | $0.36 | $0.18 | +$0.18 | $71.25M | $70.95M | N/A / N/A | N/A | +26% | Details |
| 7/31/12 |
|
Q212 | $0.27 | $0.12 | +$0.15 | $75.66M | $72.55M | N/A / N/A | N/A | +30% | Details |
